Screener
Opko Health OPK D&A
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Opko Health in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Opko Health’s 10-Q, filed July 27, 2026.
- Filed
- Jul 27, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-318090
| Line item | For the three months ended June 30, 2026 | For the three months ended June 30, 2025 | For the six months ended June 30, 2026 | For the six months ended June 30, 2025 |
|---|---|---|---|---|
| Pharmaceutical | $18,511 | $18,142 | $36,770 | $35,930 |
| Diagnostics | 3,883 | 4,885 | 7,810 | 10,584 |
| Corporate | 15 | — | 29 | — |
| $22,409 | $23,027 | $44,609 | $46,514 | |
| Revenues: | ||||
| United States | $88,809 | $114,884 | $172,313 | $231,091 |
| Ireland | 41,663 | 11,742 | 51,343 | 17,221 |
| Chile | 16,429 | 16,003 | 31,299 | 30,535 |
Item 1. Financial Statements
FAQ
- What is Opko Health's D&A?
- Opko Health (OPK) reported D&A of $22.41M in Q2 2026.
- How has Opko Health's D&A changed year-over-year?
- Opko Health's D&A decreased by 2.7% year-over-year, from $23.03M to $22.41M.
- What is the long-term trend for Opko Health's D&A?
- Over 4 years (2021 to 2025), Opko Health's D&A has grown at a 3.9% compound annual growth rate (CAGR), from $78.72M to $91.63M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Opko Health's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude